

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.: 10/518,818	First Named Inventor: Bailey et al.
371 Filing Date: Dec. 20, 2004	Attorney Docket No.: 100730-1P US
Examiner: GRAFFEO, Michel	Group Art Unit: 1614
Customer No.: 22466	Confirmation No.: 8247
Title: Novel Compounds	

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO THE RESTRICTION REQUIREMENT**

Sir:

The present Response is filed in regard to the Restriction Requirement dated July 27, 2006 in connection with the above-identified patent application.

In the Restriction Requirement, the Examiner restricted pending claims into four groups:

Group I, claim(s) 1-7, drawn to a method of inhibiting Cathepsin S.

Group II, claim(s) 9, drawn to a pharmaceutical composition.

Group III, claim(s) 10-11, drawn to a method for producing inhibition of a cysteine.

Group IV, claim(s) 12, drawn to a method for treating pain.

Applicants elect Group I, claims 1-7, with traverse.

The Examiner has further averred that claim 1 encompassed multiple and patentably distinct species, which are enumerated as follows.

Specie 1: the compound of formula (I) when A comprises an O

Specie 2: the compound of formula (I) when A comprises an O

Specie 3: the compound of formula (I) when A comprises no heteroatom.

The Examiner requests that Applicants elect a single specie. Applicants elect Specie 3, when A comprises no heteroatom, with traverse. Applicants submit that this election is sufficient for searching purposes. Should the Examiner require additional moieties to be elected,

Application No. 10/518,818  
Response Dated: Aug. 31, 2006  
Reply to Restriction Requirement of July 27, 2006

Applicants further elect the following additional moieties: R<sup>1</sup> and R<sup>2</sup> together with the nitrogen atom to which they are attached form an unsubstituted morpholine ring or a piperidine ring substituted by a group -(CH<sub>2</sub>)<sub>p</sub>-R<sup>6</sup> where p is 0 to 3 and R<sup>6</sup> is C<sub>1-6</sub> alkyl; R<sup>3</sup> is hydrogen; R<sup>4</sup> is hydrogen, R<sup>5</sup> is hydrogen or phenyl optionally substituted by C<sub>1-6</sub> alkyl or C<sub>1-6</sub> alkoxy. Claims 1-7 are readable on the election made. Support for the election made can be found, for example, in the original claims 1-6.

A petition for a one month extension of time is being filed herewith, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 100730-1P US.

Although Applicants believe no excess claim fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 100730-1P US.

Respectfully submitted,  
/Jianzhong SHEN, Reg.#48076/

---

Name: Jianzhong Shen  
Dated: 8/31/2006  
Reg. No.: 48076  
Phone No.: 302-886-8854  
Global Intellectual Property, Patents,  
AstraZeneca,  
1800 Concord Pike,  
Wilmington,  
DE-19850-5437